Results 1 to 10 of about 19,685 (183)

Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial

EClinicalMedicine, 2021
Background: Angiotensin receptor blockers (ARBs), such as telmisartan, have been postulated to treat Covid-19-induced lung inflammation. Methods: This is a parallel-group, randomized, two-arm, open-label, adaptive, multicenter superiority trial with 1:1 ...
Mariano Duarte, Facundo Pelorosso, Liliana N. Nicolosi, M. Victoria Salgado, Héctor Vetulli, Analía Aquieri, Francisco Azzato, Marcela Castro, Javier Coyle, Ignacio Davolos, Ignacio Fernandez Criado, Rosana Gregori, Pedro Mastrodonato, María C. Rubio, Sergio Sarquis, Fernando Wahlmann, Rodolfo P. Rothlin   +16 more
doaj   +3 more sources

Bioequivalence and Food Effect Assessment of Two Fixed‐Dose Combination Formulations of Telmisartan‐Hydrochlorothiazide Tablets in Chinese Healthy Subjects [PDF]

Clinical and Translational Science
This study assessed the bioequivalence and food effect of two fixed‐dose combination (FDC) formulations of telmisartan‐hydrochlorothiazide tablets (telmisartan 40 mg, hydrochlorothiazide 12.5 mg) in healthy Chinese subjects.
Minwan Hu, Man Yang, Shuyu Zhang, Jiangfan Li, Hongxian Pang, Yingzi Pei, Chao Guo, Xuhong Wang   +7 more
doaj   +2 more sources

Decoding Drug Interactions: Character and Degree of Pharmacokinetic Interactions Between Telmisartan and Sorafenib or Donafenib in Rats [PDF]

Drug Design, Development and Therapy
Ying Li,1,2,* Wenyu Du,1– 3,* Chunhui Shan,4 Zefang Yu,1 Jing An,1,2 Zhanjun Dong1,2 1Department of Pharmacy, Hebei General Hospital, Shijiazhuang, Hebei, People’s Republic of China; 2Hebei Key Laboratory of Clinical Pharmacy ...
Li Y, Du W, Shan C, Yu Z, An J, Dong Z
doaj   +2 more sources

Is the fixed-dose combination of telmisartan and hydrochlorothiazide a good approach to treat hypertension? [PDF]

Vascular Health and Risk Management, 2007
Marc P Maillard, Michel BurnierService of Nephrology, Department of Internal Medicine, Lausanne University Hospital, SwitzerlandAbstract: Blockade of the renin-angiotensin system with selective AT1 receptor antagonists is recognized as an effective mean ...
Marc P Maillard, Michel Burnier
doaj   +2 more sources

Investigating the effect of telmisartan on acrylamide-induced neurotoxicity through in vitro and in vivo methods [PDF]

Iranian Journal of Basic Medical Sciences, 2023
Objective(s):  Acrylamide (ACR) is an environmental contaminant and neurotoxin. Telmisartan is an AT1 blocker that has neuroprotective properties basically through its anti-oxidant effect.
Zahra Yazadanpanah, Mahboobeh Ghasemzadeh Rahbardar, Bibi Marjan Razavi, Hossein Hosseinzadeh   +3 more
doaj   +1 more source

Telmisartan versus metformin in downregulating myostatin gene expression and enhancing insulin sensitivity in the skeletal muscles of type 2 diabetic rat model

Frontiers in Pharmacology, 2023
Objective: Telmisartan is an angiotensin receptor blocker (ARB) that specifically blocks angiotensin II type-1 receptors (AT1R). Telmisartan has been proven to have antidiabetic effects via a variety of mechanisms, and it can be utilized in some diabetic
Ahmed Abd-Eltawab Tammam, Waleed Y. Rizg, Waleed Y. Rizg, Amy Fakhry Boushra, Maha Alhelf, Maha Alhelf, Mohammed Alissa, Ghada F. Soliman, Ghada F. Soliman, Ghada Nady Ouais, Ghada Nady Ouais, Khaled M. Hosny, Hala M. Alkhalidi, Ahmed Magdy Elebiary   +13 more
doaj   +1 more source

Telmisartan induces growth inhibition, DNA double-strand breaks and apoptosis in human endometrial cancer cells. [PDF]

PLoS ONE, 2014
Telmisartan, an angiotensin II receptor type 1 blocker, is often used as an antihypertension drug, and it has also been characterized as a peroxisome proliferator-activated receptor-gamma (PPARγ) ligand.
Naoko Koyama, Yoshihiro Nishida, Terukazu Ishii, Toshie Yoshida, Yuichi Furukawa, Hisashi Narahara   +5 more
doaj   +1 more source

Anti-Apoptosis of Podocytes and Pro-Apoptosis of Mesangial Cells for Telmisartan in Alleviating Diabetic Kidney Injury

Frontiers in Pharmacology, 2022
Podocytes damage and mesangial cells expansion are two important pathological manifestations of glomerular injury in early diabetes. Telmisartan, as an angiotensin type 1 (AT1) receptor inhibitor, could improve advanced glycation end (AGE) products or ...
Xin Wei, Yabin Ma, Ya Li, Wenzhao Zhang, Yuting Zhong, Yue Yu, Li-Chao Zhang, Zhibin Wang, Ye Tu   +8 more
doaj   +1 more source

Central blood pressure lowering effect of telmisartan‐rosuvastatin single‐pill combination in hypertensive patients combined with dyslipidemia: A pilot study

The Journal of Clinical Hypertension, 2021
This multicenter, phase 4, Prospective Randomized Open, Blinded End‐point (PROBE) study aimed to evaluate safety and efficacy of telmisartan/rosuvastatin single‐pill combination (SPC) therapy on lowering central blood pressure (BP) compared with ...
JungMin Choi, Ki‐Chul Sung, Sang‐Hyun Ihm, Chang‐Hwan Yoon, Seung Woo Park, Sung‐Ha Park, Jang‐Young Kim, Sung‐Uk Kwon, Hae‐Young Lee   +8 more
doaj   +1 more source

Critical Analysis and Optimization of Stoichiometric Ratio of Drug-Coformer on Cocrystal Design: Molecular Docking, In Vitro and In Vivo Assessment

Pharmaceuticals, 2023
In this present research, an attempt has been made to address the influence of drug-coformer stoichiometric ratio on cocrystal design and its impact on improvement of solubility and dissolution, as well as bioavailability of poorly soluble telmisartan ...
Manami Dhibar, Santanu Chakraborty, Souvik Basak, Paramita Pattanayak, Tanmay Chatterjee, Balaram Ghosh, Mohamed Raafat, Mohammed A. S. Abourehab   +7 more
doaj   +1 more source